Ubs Asset Management Americas Inc Vaxcyte, Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 295,762 shares of PCVX stock, worth $34.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
295,762
Previous 108,012
173.82%
Holding current value
$34.2 Million
Previous $7.38 Million
202.68%
% of portfolio
0.01%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PCVX
# of Institutions
286Shares Held
110MCall Options Held
248KPut Options Held
109K-
Black Rock Inc. New York, NY9.94MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.13 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$1.02 Billion0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$948 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$531 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.85B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...